Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota.
microbiota manipulation
precision medicine
response to therapies
tissue microbiota
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
09
2022
accepted:
15
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
The role of the intestinal microbiota in the promotion, progression, and response to therapies is gaining importance, but recent studies confirm the presence of microbiota also in the tumor, thus becoming a component of the tumor microenvironment. There is not much knowledge on the characteristics and mechanisms of action of the tumor resident microbiota, but there are already indications of its involvement in conditioning the response to therapies. In this review, we discuss recent publications on the interaction between microbiota and anticancer treatments, mechanisms of resistance and possible strategies for manipulating the microbiota that could improve treatments in a personalized medicine perspective.
Identifiants
pubmed: 36684442
doi: 10.3389/fcell.2022.1048360
pii: 1048360
pmc: PMC9845623
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1048360Informations de copyright
Copyright © 2023 Pirini, Cortesi, Tumedei, Zanoni, Ravaioli and Bravaccini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gut Microbes. 2013 May-Jun;4(3):181-92
pubmed: 23511582
Cell Host Microbe. 2019 Feb 13;25(2):285-299.e8
pubmed: 30763538
Crit Care. 2017 Jun 4;21(1):129
pubmed: 28583189
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12005-E12014
pubmed: 30509983
Microbiome. 2022 Feb 21;10(1):34
pubmed: 35189979
Nat Commun. 2021 Feb 16;12(1):1067
pubmed: 33594081
Drug Metab Rev. 2018 Aug;50(3):357-368
pubmed: 30227749
J Exp Clin Cancer Res. 2009 Dec 16;28:155
pubmed: 20015348
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8668-73
pubmed: 23610422
Nature. 2019 Oct;574(7777):264-267
pubmed: 31578522
Oral Microbiol Immunol. 2003 Oct;18(5):278-84
pubmed: 12930518
Probiotics Antimicrob Proteins. 2019 Dec;11(4):1155-1162
pubmed: 30311185
Cancer Discov. 2018 Apr;8(4):403-416
pubmed: 29567829
Front Oncol. 2021 Mar 10;11:604584
pubmed: 33796451
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
PLoS One. 2014 Jan 08;9(1):e83744
pubmed: 24421902
Gut. 2014 Dec;63(12):1932-42
pubmed: 24658599
Nat Med. 2022 Apr;28(4):704-712
pubmed: 35228755
J Thorac Oncol. 2020 Jul;15(7):1147-1159
pubmed: 32173463
Front Microbiol. 2018 May 15;9:951
pubmed: 29867857
Mol Nutr Food Res. 2017 Jan;61(1):
pubmed: 27500859
Front Biosci (Landmark Ed). 2010 Jan 01;15(2):397-417
pubmed: 20036827
Microbiome. 2020 Mar 11;8(1):33
pubmed: 32160905
Theranostics. 2015 Oct 06;5(12):1328-42
pubmed: 26516371
Immunity. 2016 Oct 18;45(4):931-943
pubmed: 27717798
Science. 2021 Dec 24;374(6575):1632-1640
pubmed: 34941392
Cell. 2022 Apr 14;185(8):1356-1372.e26
pubmed: 35395179
Metabolites. 2021 Nov 04;11(11):
pubmed: 34822416
J Natl Cancer Inst. 2021 Feb 1;113(2):162-170
pubmed: 32294209
Cancer Gene Ther. 2003 Oct;10(10):737-44
pubmed: 14502226
Cell. 2021 Oct 14;184(21):5338-5356.e21
pubmed: 34624222
Appl Environ Microbiol. 2016 Jul 29;82(16):5039-48
pubmed: 27342554
Science. 2021 Mar 26;371(6536):
pubmed: 33766858
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Mol Ther. 2010 Mar;18(3):635-42
pubmed: 20051939
Science. 2019 Mar 29;363(6434):
pubmed: 30923196
Nutr Cancer. 2008;60(6):757-67
pubmed: 19005975
Science. 2021 Feb 5;371(6529):595-602
pubmed: 33542131
Cell. 2015 Jan 29;160(3):447-60
pubmed: 25619688
Front Microbiol. 2020 Feb 25;11:301
pubmed: 32158441
Nat Commun. 2016 May 11;7:11535
pubmed: 27168102
Clin Cancer Res. 2008 Jul 1;14(13):4259-66
pubmed: 18594008
Mol Ther. 2013 Nov;21(11):1985-95
pubmed: 23922014
Sci Rep. 2015 Sep 29;5:14554
pubmed: 26416623
Sci Transl Med. 2014 Aug 13;6(249):249ra111
pubmed: 25122639
Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502
pubmed: 28611480
ACS Nano. 2020 Nov 24;14(11):14391-14416
pubmed: 33138351
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
PLoS Pathog. 2017 Jul 13;13(7):e1006440
pubmed: 28704539
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28807909
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365
pubmed: 28270698
Gastroenterology. 2018 Aug;155(2):529-541.e5
pubmed: 29689266
Cell Host Microbe. 2019 Dec 11;26(6):764-778.e5
pubmed: 31757768
Clin Nutr. 2017 Feb;36(1):93-99
pubmed: 26644166
Front Microbiol. 2018 Jul 23;9:1614
pubmed: 30083140
Nat Med. 2019 May;25(5):730-733
pubmed: 31068712
mBio. 2020 Mar 10;11(2):
pubmed: 32156803
Nature. 2021 Apr;592(7852):138-143
pubmed: 33731925
Cancer Immunol Immunother. 2012 Nov;61(11):1977-87
pubmed: 22527247
Br J Cancer. 2013 Jun 11;108(11):2281-90
pubmed: 23640395
Genome Biol. 2016 Jul 28;17(1):163
pubmed: 27468850
Int J Antimicrob Agents. 2014 Jun;43(6):485-96
pubmed: 24721232
Biochem J. 2012 Jul 1;445(1):113-23
pubmed: 22475552
Cancer Cell. 2021 Sep 13;39(9):1202-1213.e6
pubmed: 34329585
Science. 2017 Sep 15;357(6356):1156-1160
pubmed: 28912244
Cancer Gene Ther. 2008 Jun;15(6):393-401
pubmed: 18369382
Clin Infect Dis. 2001 Dec 15;33(12):1959-67
pubmed: 11702290